Zinc Ion

Zinc Ion

SCHEMBL192815

Nc1ccc(S(=O)(=O)[O-])cc1.Nc1ccc(S(=O)(=O)[O-])cc1.[Zn+2]

nearest known ligand 0.62

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.62
HTR6 P50406 2/20 0.62
LMNA P02545 2/20 0.62
MPO P05164 1/20 0.62
CYP3A4 P08684 1/20 0.62
CYP2C9 P11712 1/20 0.62
CA2 P00918 5/20 0.59
CA9 Q16790 5/20 0.59
CA1 P00915 4/20 0.59
CA12 O43570 4/20 0.59
CA14 Q9ULX7 2/20 0.59
AGO2 Q9UKV8 2/20 0.59
CA4 P22748 2/20 0.59
TDP1 Q9NUW8 2/20 0.59
USP2 O75604 1/20 0.59
CA6 P23280 1/20 0.59
CA5A P35218 1/20 0.59
CA7 P43166 1/20 0.59
CA13 Q8N1Q1 1/20 0.59
CA5B Q9Y2D0 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL4230663 0.97 TSHR (0.59) TSHRHTR6LMNAMPOCYP3A4
SCHEMBL31212650 0.94 TSHR (0.62) TSHRHTR6LMNAMPOCYP3A4
SCHEMBL31108168 0.94 TSHR (0.62) TSHRHTR6LMNAMPOCYP3A4
SCHEMBL29870132 0.94 TSHR (0.62) TSHRHTR6LMNAMPOCYP3A4
SCHEMBL2289878 0.94 TSHR (0.62) TSHRHTR6LMNAMPOCYP3A4
Silver SCHEMBL30882004 0.94 TSHR (0.62) TSHRHTR6LMNAMPOCYP3A4
SCHEMBL11316984 0.94 TSHR (0.62) TSHRHTR6LMNAMPOCYP3A4
SCHEMBL646075 0.94 TSHR (0.62) TSHRHTR6LMNAMPOCYP3A4
SCHEMBL678391 0.94 TSHR (0.62) TSHRHTR6LMNAMPOCYP3A4
Potassium Ion SCHEMBL5776427 0.94 TSHR (0.62) TSHRHTR6LMNAMPOCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1092 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119173060-A Application of potassium taurine-based perovskite solar cell and preparation method thereof 浙大宁波理工学院 2024-12-20 CN claimed
CN-114015047-B S-containing polymer and preparation method thereof 四川大学 2022-09-23 CN claimed
US-20220169680-A1 CELL-PENETRATING PEPTIDE BASED ON INFLUENZA VIRUS M2 PROTEIN INSTITUTE OF BASIC MEDICAL SCIENCES CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2022-06-02 US claimed
CN-114015047-A S-containing polymer and preparation method thereof 四川大学 2022-02-08 CN claimed
EP-3912989-A1 CELL-PENETRATING PEPTIDE BASED ON INFLUENZA VIRUS M2 PROTEIN Institute of Basic Medical Sciences Chinese Academy of Medical Sciences (CN) 2021-11-24 EP claimed
CN-113582217-A Preparation method of ZnO/carbon composite interlayer 湖南师范大学 2021-11-02 CN claimed
CN-112851931-A Corrosion-resistant polyarylether resin, corrosion-resistant separation membrane and preparation method thereof 四川大学 2021-05-28 CN claimed
CN-111569680-B Polyarylether ultrafiltration membrane, nanofiltration membrane, preparation method and method for reversible conversion of ultrafiltration membrane and nanofiltration membrane 四川大学 2021-03-19 CN claimed
CN-111569680-A Polyarylether ultrafiltration membrane, nanofiltration membrane, preparation method and method for reversible conversion of ultrafiltration membrane and nanofiltration membrane 四川大学 2020-08-25 CN claimed
US-8268352-B2 Modified release composition for highly soluble drugs TORRENT PHARMACEUTICALS LIMITED (IN) 2012-09-18 US claimed
US-20070093462-A1 Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA 2007-04-26 US claimed
WO-2007044693-A2 MULTI-FUNCTIONAL IONIC LIQUID COMPOSITIONS THE UNIVERSITY OF ALABAMA (US) 2007-04-19 WO claimed
CN-1826129-A Methods and compositions relating to isoleucine boroproline compounds POINT THERAPEUTICS INC (US) 2006-08-30 CN claimed
US-20060024365-A1 Novel dosage form VAYA NAVIN 2006-02-02 US claimed
US-20060018933-A1 Novel drug delivery system TORRENT PHARMACEUTICALS LIMITED (IN) 2006-01-26 US claimed
US-20060018934-A1 Novel drug delivery system TORRENT PHARMACEUTICALS LIMITED (IN) 2006-01-26 US claimed
EP-1578434-A2 METHODS AND COMPOSITIONS RELATING TO ISOLEUCINE BOROPROLINE COMPOUNDS Point Therapeutics, Inc. (US) 2005-09-28 EP claimed
US-20040131628-A1 Nucleic acids for the treatment of disorders associated with microorganisms BRATZLER ROBERT L (US) 2004-07-08 US claimed
US-20040077601-A1 Methods and compositions relating to isoleucine boroproline compounds POINT THERAPEUTICS, INC. 2004-04-22 US claimed
WO-2004004658-A2 METHODS AND COMPOSITIONS RELATING TO ISOLEUCINE BOROPROLINE COMPOUNDS POINT THERAPEUTICS, INC. (US) 2004-01-15 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093462-A1 Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients SLC5A6, PNLIP, IPMK TSHR 4253/4885HTR6 1329/4885LMNA 1556/4885
US-20040077601-A1 Methods and compositions relating to isoleucine boroproline compounds BCAT1, BCAT2, APOB TSHR 1945/4885HTR6 936/4885LMNA 250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.